Artificial intelligence startup OpenEvidence inked a multi-year content agreement with the JAMA Network to use content from 13 medical journals to inform answers on its platform.
OpenEvidence developed an AI-powered medical search engine and generative AI chatbot exclusively for doctors that summarizes and simplifies evidence-based medical information.
The JAMA Network, published by the American Medical Association, includes the Journal of the American Medical Association, JAMA Network Open and 11 JAMA specialty journals. Under the agreement, all published content, including full text and multimedia, will inform answers delivered on the OpenEvidence clinical decision support platform.
"Clinicians seek reliable information to guide their care of patients and want the best scientific evidence readily accessible, said Dr. Kirsten Bibbins-Domingo, Ph.D., M.D. and Editor-in-Chief of JAMA and the JAMA Network. "OpenEvidence has rapidly established itself as a favored resource among clinicians, and I am pleased for the JAMA Network to join OpenEvidence as a content partner, making the peer-reviewed science from across our 13 journals more accessible to practicing clinicians."
Founded in 2022 by Daniel Nadler, the company touts that it's the most widely used medical search engine among U.S. clinicians, claiming more than a third of doctors in the United States use its platform.
More than 50,000 verified clinicians register for its platform each month, the company said in a press release, and OpenEvidence is actively used across more than 10,000 hospitals and medical centers nationwide.
Nadler told STAT that the company has registered 350,000 doctors on its platform and handles "7.2 million clinical consultations a month."
In February, the company announced a $75 million fundraise backed by Sequoia at a valuation of $1 billion, CNBC reported.
"The JAMA Network is well known as a trusted source of the highest-quality scientific evidence that can inform clinical decisions," Nadler, CEO of OpenEvidence, said in a statement. "Now, through this partnership, the clinical trials, observational studies, guidelines, and clinical reviews from nearly every major specialty and sub-specialty that the JAMA Network covers will be delivered in a way that clinicians need: immediately and in the palm of their hand."
The company recently announced a similar deal with the NEJM Group, publisher of the New England Journal of Medicine (NEJM), for all published content and multimedia from 1990 forward from NEJM, NEJM Evidence, NEJM AI, NEJM Catalyst, and NEJM Journal Watch.
Last year, medical information company Elsevier Health partnered with OpenEvidence to develop what it called a next-generation clinical decision support tool. Called ClinicalKey AI, it combines the most recent and reputable evidence-based medical content with generative artificial intelligence to help physicians at the point of care.
The digital transformation of healthcare has mostly fallen short in its efforts to deliver trusted, evidence-based clinical decision support to clinicians when they need it most, according to Robert Wachter, M.D., Chair of the Department of Medicine at UCSF, But, AI represents a leap forward.
"The partnership between JAMA, a cornerstone of medical research and analysis for more than a century, and OpenEvidence, my preferred platform for AI-powered clinical insights, represents a significant step toward fulfilling that promise. I'm confident that both clinicians and patients will benefit," Wachter said in a statement.
OpenEvidence is competing with companies like UpToDate, an evidence-based clinical decision support resource owned by Wolters Kluwer. UpToDate, which has been in the market more than 30 years, also is teaming up with AI companies. The company is working with Abridge to integrate UpToDate into the startup's AI-based medical note-taking tool, and it's also partnering with Corti AI.